REGENERON PHARMACEUTICALS, INC. Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31)
REGENERON PHARMACEUTICALS, INC. (REGN) reported Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31) of -$335.80 million for the 3-month period ending 2012-12-31, per its 10-K filed 2013-02-15.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefitContinuingOperations · last filed 2013-02-15
- REGENERON PHARMACEUTICALS, INC. income tax expense (benefit), continuing operations (deprecated 2013-01-31) for the quarter ending 2012-12-31 was -$335.80M.
- REGENERON PHARMACEUTICALS, INC. income tax expense (benefit), continuing operations (deprecated 2013-01-31) for fiscal 2012 was -$335.85M.
| Period end | Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31) 3 month | Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31) 12 month |
|---|---|---|
| 2012-12-31 | -$335.80M 10-K · filed 2013-02-15 | -$335.85M 10-K · filed 2013-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |